Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

IBAB.BR BE Equity

Ion Beam Applications
Euronext Brussels+ CompareTear sheet →
Unclassified · FY ends Dec 31
€15.90
-0.14 (-0.87%)
EUR · as of 2026-08-17 · marketstack
3 registered studies · 3 active

Studies where IBAB.BR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

3 interventional

government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan)NCT07152353Short term efficacy evaluationOpen-label · TreatmentNot applicableActive, not recruitingDevice: Proton Beam Therapy (PBT)Solid Tumor, Adult47Oct 2026≤ 73 d2026-01-07
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)NCT07153094Short term efficacy evaluationOpen-label · TreatmentNot applicableActive, not recruitingDevice: Proton Beam Therapy (PBT)Solid Tumor, Adult47Oct 2026≤ 73 d2026-01-16
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)NCT07137195Short term efficacy evaluationOpen-label · TreatmentNot applicableActive, not recruitingDevice: Proton Beam Therapy (PBT)Solid Tumor, Adult472026-09-05in 17 d2026-02-27

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19